Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
about
Clinical trials in severe sepsis with drotrecogin alfa (activated)Human recombinant activated protein C for severe sepsisHuman recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsHuman recombinant activated protein C for severe sepsisHuman recombinant activated protein C for severe sepsisSustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAbSafety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsisCoagulation in sepsis: all bugs bite equallyA meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis.Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.Alterations in the human lung proteome with lipopolysaccharide.Review: Immunology of sinusitis, trauma, asthma, and sepsis.Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factorActivated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impactActivated protein C action in inflammationTherapeutic interventions in sepsis: current and anticipated pharmacological agentsRole of human recombinant activated protein C and low dose corticosteroid therapy in sepsisAn updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?Drotrecogin alfa: a new approach in the treatment of severe sepsis.Recombinant human activated protein C for use in severe sepsis.Emerging therapies in severe sepsis.The efficacy of activated protein C for the treatment of sepsis: incorporating observational evidence with a Bayesian approachUse of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis.Strategies to optimize drotrecogin alfa (activated) use: guidelines and therapeutic controversies.Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.Human severe sepsis cytokine mixture increases β2-integrin-dependent polymorphonuclear leukocyte adhesion to cerebral microvascular endothelial cells in vitro.The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.Treatment with recombinant human activated protein C: one size does not fit all.Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis.Drotrecogin alfa: a role in emergency department treatment of severe sepsis?Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial.Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity.Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
P2860
Q21195024-043398C5-4DAD-418A-8F50-3CAEF7FE1D74Q24201123-19F5E023-A4C5-4DD3-BF47-F7FDEBF4FEFEQ24202128-33431778-7FE0-4FFC-AEA0-04C89799D194Q24235181-CF3513F5-C11E-4CC8-AB3F-B0C9FC5F56B8Q24242859-B59FA39F-1C49-43BB-89C3-DF91F5787EABQ24594601-6A28671D-6C5A-490C-BB27-D057685B5212Q24794551-A3709A6B-4E8B-422B-9AD5-97100ABF81E6Q24805503-254BCD51-F826-4AC4-9D63-4EC8504EE481Q24816510-8420DAB7-A436-4087-9356-518C8C7239CBQ25255548-3DDD2F77-8A56-419D-BA5B-C4E32DD40B74Q33338424-01EF08EB-9D0D-4B72-B487-2CE9AD5B042AQ33443562-5AAC0978-4568-4D6B-84C8-E513732C946FQ33564143-55043A65-D33A-4AF2-89F4-30DF053566EDQ33602407-E17D3A5A-AF57-4AEE-9633-C778696601E6Q33798916-9956533F-69ED-4EE7-A5FA-F3F27D772B15Q33846825-22A00C0A-5B94-4DBA-931F-E4A9BCE224A2Q34427050-0F4814B0-A3BC-451B-8805-D159B3B4DBEFQ34469113-6BE24795-931B-49AF-9A68-83577D5A7B39Q34486385-7519FA99-1805-4197-8CA6-287ADA7A26D0Q34568205-A696E4A9-8682-4AF6-A7EE-96A40AEDB615Q34779800-BBD9ED32-6BCB-490A-985A-C75940A99215Q34796994-92C02AA3-6FE2-4602-8316-CCDA146ED8C1Q34938586-063C5813-56F3-4698-B0F4-74FE96944C70Q34981434-84C26707-2CE7-4AAB-BB51-824FD08E5F36Q34999600-4C55C2D1-8713-4A09-98DA-4B507B9ABDE4Q35030570-75E3D168-578B-4953-8B95-BB1082CAE1F0Q35030573-B3D740F4-1C69-49E0-B729-17CD14DDDCFAQ35030587-A06123A4-8711-412C-8AE7-14CBE826BDE3Q35059326-DB649855-B194-4733-BF76-907DC59ECC35Q35537959-0CC64D49-ACF6-413B-930F-C40FC6F0C976Q35548184-6E6904F6-17E7-4E69-B87B-0B095FC8B8AAQ35567111-12A22A81-A1F2-4590-8314-C642B9847D26Q35794980-96007F30-711C-47C1-AE6E-E5C5079ED3E7Q35850483-EF7BB02B-9BC4-4482-A32F-7FDFF1C0DDF7Q35925664-CA89A971-50B2-4045-8736-7219D578E5E6Q35974913-2075BCBE-7FE9-4C7A-8AF7-A46C1A3F5131Q36228995-075D190C-F97B-4533-AB9A-C47EE0E58D05Q36259602-E9EBD0E1-A7CA-48F1-9FC7-AE1A450E9BD6Q36295952-CEDB2D7D-5409-4411-BCCF-7E17BB352949Q36349735-A9EFA60D-607D-41BB-97BD-B6064D61AFEF
P2860
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Safety and dose relationship o ...... coagulopathy in severe sepsis.
@en
type
label
Safety and dose relationship o ...... coagulopathy in severe sepsis.
@en
prefLabel
Safety and dose relationship o ...... coagulopathy in severe sepsis.
@en
P2093
P1476
Safety and dose relationship o ...... coagulopathy in severe sepsis.
@en
P2093
Bernard GR
Helterbrand JD
Rosenfeld BA
Russell JA
Stasek JE Jr
P304
P356
10.1097/00003246-200111000-00003
P407
P577
2001-11-01T00:00:00Z